A study recently published in Gastroenterology presents a possible breakthrough in the treatment of irritable bowel syndrome.
According to a June 5 news release, the trial included 238 patients across eight U.S. academic medical centers, including Rochester, Minn.-based Mayo Clinic, Cleveland Clinic and the University of Michigan in Ann Arbor. The trial compared outcomes between a treatment group who eliminated foods identified by Bioamerica’s inFoods IBS test versus a control group following a placebo diet.
Here are four key findings from the study:
1. Of patients in the treatment group, 59.6% achieved the FDA responder definition for abdominal pain reduction, compared to 42.2% in the control group.
2. Among patients with IBS-C who received the treatment, 67.1% reached the FDA responder benchmark for abdominal pain reduction, compared to 35.8% in the control group.
3. Among patients with IBS-M in the treatment group, 66% met the benchmark compared with 29.5% in the control group.
4. “Our diets are complex, and identifying individual food triggers can be extremely challenging,” said Anthony Lembo, MD, vice chair of research at Cleveland Clinic’s Digestive Disease Institute. “This test offers a data-driven path to help IBS patients reduce symptoms by identifying specific problematic foods.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.